Examination on the differences of the symptoms which should be given priority to treatment from the perspective of major depressive disorder patients vs their physicians

Not Applicable

• Conditions: Major depressive disorder (MDD)

• Registration Number: JPRN-UMIN000039967
• Lead Sponsor: Takeda Pharmaceutical Company Limited.

Brief Summary

Of the 2618 patients, 828 were assigned to 326 physicians. Fewer physicians than patients reported physical symptoms in the mild stage and cognitive symptoms in the severe and mild stages. Social function was deemed to be lower by physicians than by patients across all stages. Regarding treatment expectations, more physicians than patients reported "return to a normal life" in the mild and remission stages, and more patients than physicians reported "reduction of side effects" in the severe and mild stages.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-27
• Study Completion: 2020-05-14
• Results First Posted: 2021-09-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 828

Inclusion Criteria

Not provided

Exclusion Criteria

[Survey in patients] 1) Physicians who are employed by a pharmaceutical company or marketing agency. 2) Patients who show 9 or less score of PHQ-9 survey in their most severe MDD symptoms in the past. [Survey in physicians] 1)Physicians themselves or their relatives are employed by a pharmaceutical company or marketing agency.

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified